ATE298765T1 - Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren - Google Patents

Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren

Info

Publication number: ATE298765T1
Authority: AT; Austria
Prior art keywords: beta; peptide; amyloid peptide; compounds; amino
Prior art date: 1996-08-27

Application number

AT97940663T

Other languages

English (en)

Inventor

Mark A Findeis

Malcolm L Gefter

Gary Musso

Ethan R Signer

James Wakefield

Susan Molineaux

Joseph Chin

Jung-Ja Lee

Michael Kelley

Sonja Komar-Panicucci

Christopher C Arico-Muendel

Kathryn Phillips

Neil J Hayward

Original Assignee

Praecis Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1997-08-27

Publication date

2005-07-15

1996-08-27 Priority claimed from US08/703,675 external-priority patent/US6303567B1/en

1997-08-27 Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE298765T1 publication Critical patent/ATE298765T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
150000008574 D-amino acids Chemical class 0.000 title abstract 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract 4
230000006919 peptide aggregation Effects 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
125000003368 amide group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
229930182819 D-leucine Natural products 0.000 abstract 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
229930182832 D-phenylalanine Natural products 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000003367 polycyclic group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Medicinal Chemistry (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Zoology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT97940663T 1996-08-27 1997-08-27 Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren ATE298765T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/703,675 US6303567B1 (en)	1995-03-14	1996-08-27	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US89734297A	1997-07-21	1997-07-21
PCT/US1997/015166 WO1998008868A1 (en)	1996-08-27	1997-08-27	MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS

Publications (1)

Publication Number	Publication Date
ATE298765T1 true ATE298765T1 (de)	2005-07-15

Family

ID=27107183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97940663T ATE298765T1 (de)	1996-08-27	1997-08-27	Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren

Country Status (10)

Country	Link
EP (2)	EP1586584A1 (de)
JP (1)	JP2001500852A (de)
AT (1)	ATE298765T1 (de)
AU (1)	AU741199B2 (de)
CA (1)	CA2262453A1 (de)
DE (1)	DE69733655T2 (de)
DK (1)	DK0929574T3 (de)
ES (1)	ES2245003T3 (de)
PT (1)	PT929574E (de)
WO (1)	WO1998008868A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277826B1 (en)	1996-08-27	2001-08-21	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) *	1995-10-27	1999-11-16	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0866805A1 (de)	1995-12-12	1998-09-30	Karolinska Innovations AB	Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
WO1998030229A1 (en) *	1997-01-10	1998-07-16	Massachusetts Institute Of Technology	TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
EP1870419A3 (de) *	1999-03-04	2008-01-02	Praecis Pharmaceuticals Incorporated	Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren
NZ514414A (en) *	1999-03-04	2004-02-27	Praecis Pharm Inc	Modulators of beta-amyloid peptide aggregation comprising D-amino acids
AU4529800A (en) *	1999-05-05	2000-11-21	Neurochem, Inc.	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2001034631A2 (en) *	1999-11-05	2001-05-17	Axonyx, Inc.	PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
KR20020073341A (ko) *	1999-11-29	2002-09-23	뉴로켐, 인크.	알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용 백신
CA2398567A1 (en) *	2000-02-11	2001-08-16	Praecis Pharmaceuticals Incorporated	Methods for enhancing the bioavailability of a drug
GB2363984A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en)	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 7-hydroxyepiandrosterone
WO2002035987A2 (en)	2000-11-03	2002-05-10	Massachusetts Institute Of Technology	METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
US7067550B2 (en)	2000-11-03	2006-06-27	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's Disease
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
JP5057628B2 (ja) *	2001-01-17	2012-10-24	ツィンメル・ロベール・アッシュ	ポリペプチド・ドラッグ物質および他の難吸収性活性成分を含む組成物の経口および非経口投与後の薬理活性を強化させる組成物および方法
EP1459764A4 (de) *	2001-12-26	2006-08-16	Takeda Pharmaceutical	Mittel zur behandlung von leichten erkennungsstörungen
US20040052928A1 (en)	2002-09-06	2004-03-18	Ehud Gazit	Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20050148650A1 (en)	2002-03-01	2005-07-07	Shigenori Ohkawa	Antidepressant
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US6846640B2 (en)	2002-04-30	2005-01-25	Pharmacia & Upjohn Company	Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
CA2530927A1 (en)	2003-06-30	2005-01-06	Tel Aviv University Future Technology Development L.P.	Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
JP2008523815A (ja)	2004-12-15	2008-07-10	エランファーマインターナショナルリミテッド	認知の改善における使用のためのヒト化アミロイドβ抗体
US7812025B2 (en)	2005-08-12	2010-10-12	Takeda Pharmaceutical Company Limited	Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
EP2089419A2 (de) *	2006-10-27	2009-08-19	Zapaloid Limited	Inhibierung der beta-amyloid-aggregation
US7842662B2 (en)	2006-11-10	2010-11-30	Cara Therapeutics, Inc.	Synthetic peptide amide dimers
JP5244810B2 (ja)	2006-11-10	2013-07-24	カラセラピューティクスインコーポレイテッド	合成ペプチドアミド
US7713937B2 (en)	2006-11-10	2010-05-11	Cara Therapeutics, Inc.	Synthetic peptide amides and dimeric forms thereof
US8906859B2 (en)	2006-11-10	2014-12-09	Cera Therapeutics, Inc.	Uses of kappa opioid synthetic peptide amides
US8236766B2 (en)	2006-11-10	2012-08-07	Cara Therapeutics, Inc.	Uses of synthetic peptide amides
AU2008215948A1 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of AD and related conditions
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
ES2498040T3 (es)	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US8288390B2 (en)	2009-03-10	2012-10-16	Takeda Pharmaceutical Company Limited	Benzofuran derivatives
AU2011313150A1 (en)	2010-10-07	2013-04-18	Takeda Pharmaceutical Company Limited	1,4-oxazepane derivatives
AU2011330768A1 (en)	2010-11-15	2013-05-30	Merz Pharma Gmbh & Co. Kgaa	Dipeptide analogs for treating conditions associated with amyloid fibril formation
HUE043171T2 (hu)	2011-10-07	2019-08-28	Takeda Pharmaceuticals Co	Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
EP2927229B1 (de)	2012-10-16	2018-09-05	Takeda Pharmaceutical Company Limited	Zur vorbeugung oder behandlung von neurodegenerativen erkrankungen oder epilepsie geeignete benzol-kondensierte fünfgliedrige stickstoff enthaltende heteroaromatische verbindungen
UA115156C2 (uk)	2012-12-11	2017-09-25	Такеда Фармасьютікал Компані Лімітед	Гетероциклічна сполука
JP6272833B2 (ja)	2013-04-04	2018-01-31	武田薬品工業株式会社	複素環化合物
EP2982666B1 (de)	2013-04-04	2019-08-07	Takeda Pharmaceutical Company Limited	Heterocyclische verbindung
EP3152198B1 (de)	2014-06-09	2019-02-27	Takeda Pharmaceutical Company Limited	Radioaktiv markierte verbindungen
HRP20220127T1 (hr)	2016-02-04	2022-04-15	Takeda Pharmaceutical Company Limited	Supstituirani spoj piperidina i njegova uporaba
WO2018164191A1 (ja)	2017-03-08	2018-09-13	武田薬品工業株式会社	置換ピロリジン化合物およびその用途
JP7114594B2 (ja)	2017-07-28	2022-08-08	武田薬品工業株式会社	複素環化合物
MY202221A (en)	2017-08-03	2024-04-17	Takeda Pharmaceuticals Co	Heterocyclic compound and use thereof
WO2019189945A1 (en)	2018-03-28	2019-10-03	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
US12077522B2 (en)	2018-06-29	2024-09-03	Takeda Pharmaceutical Company Limited	Heterocyclic compound and application thereof
WO2020153414A1 (ja)	2019-01-24	2020-07-30	武田薬品工業株式会社	複素環化合物及びその用途
TW202523658A (zh)	2019-05-24	2025-06-16	美商賽吉醫療公司	化合物、組合物及使用方法
KR20220062361A (ko)	2019-09-13	2022-05-16	다케다 야쿠힌 고교 가부시키가이샤	과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
CA3154321A1 (en)	2019-09-13	2021-03-18	Takeda Pharmaceutical Company Limited	Tak-925 for use in treating narcolepsy
JP2021050161A (ja)	2019-09-25	2021-04-01	武田薬品工業株式会社	複素環化合物及びその用途
JP2021080177A (ja)	2019-11-14	2021-05-27	武田薬品工業株式会社	複素環化合物及びその用途
CA3163200A1 (en)	2019-11-27	2021-06-03	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JP2021183587A (ja)	2020-05-22	2021-12-02	武田薬品工業株式会社	複素環化合物
WO2022115620A1 (en)	2020-11-25	2022-06-02	Sage Therapeutics, Inc.	4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
AR125073A1 (es)	2021-03-12	2023-06-07	Takeda Pharmaceuticals Co	Uso de un agonista del receptor de orexina 2 para el tratamiento de una enfermedad o trastorno mediados por orexina
US20240165092A1 (en)	2021-04-02	2024-05-23	Takeda Pharmaceutical Limited Company	Use of an orexin 2 receptor agonist for post operation recovery
EP4435096A4 (de)	2021-11-17	2025-11-26	Takeda Pharmaceuticals Co	Zellherstellungsverfahren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
WO1994019692A1 (en) *	1993-02-18	1994-09-01	The General Hospital Corporation	Alzheimer's disease therapeutics
JPH11514333A (ja) *	1995-03-14	1999-12-07	プレーシスファーマスーティカルズインコーポレイテッド	アミロイドの凝集の調節剤
EP0866805A1 (de) *	1995-12-12	1998-09-30	Karolinska Innovations AB	Peptide, das die KLVFF Sequenz von beta-Amyloid bindet

1997
- 1997-08-27 DE DE69733655T patent/DE69733655T2/de not_active Expired - Fee Related
- 1997-08-27 PT PT97940663T patent/PT929574E/pt unknown
- 1997-08-27 EP EP05013789A patent/EP1586584A1/de not_active Withdrawn
- 1997-08-27 JP JP10511914A patent/JP2001500852A/ja not_active Ceased
- 1997-08-27 ES ES97940663T patent/ES2245003T3/es not_active Expired - Lifetime
- 1997-08-27 EP EP97940663A patent/EP0929574B1/de not_active Expired - Lifetime
- 1997-08-27 CA CA002262453A patent/CA2262453A1/en not_active Abandoned
- 1997-08-27 DK DK97940663T patent/DK0929574T3/da active
- 1997-08-27 WO PCT/US1997/015166 patent/WO1998008868A1/en not_active Ceased
- 1997-08-27 AU AU42387/97A patent/AU741199B2/en not_active Ceased
- 1997-08-27 AT AT97940663T patent/ATE298765T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT929574E (pt)	2005-11-30
JP2001500852A (ja)	2001-01-23
AU4238797A (en)	1998-03-19
WO1998008868A1 (en)	1998-03-05
AU741199B2 (en)	2001-11-22
EP0929574A1 (de)	1999-07-21
CA2262453A1 (en)	1998-03-05
EP0929574B1 (de)	2005-06-29
EP1586584A1 (de)	2005-10-19
DK0929574T3 (da)	2005-10-31
ES2245003T3 (es)	2005-12-16
DE69733655T2 (de)	2006-04-27
HK1021741A1 (en)	2000-06-30
DE69733655D1 (de)	2005-08-04

Legal Events

Date

Code

Title

Description

2006-05-15

UEP

Publication of translation of european patent specification

Ref document number: 0929574

Country of ref document: EP

2010-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69733655D1 (de)	2005-08-04	beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
ATE366259T1 (de)	2007-07-15	Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
DE69739035D1 (de)	2008-11-20	Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
DE69129865D1 (de)	1998-08-27	Osteogene peptide
ATE417925T1 (de)	2009-01-15	Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE69532996D1 (de)	2004-06-09	Peptidanaloge des menschlichen basischen myelinproteins
NO920671D0 (no)	1992-02-20	Fremgangsmaate for aktivering av rekombinante proteiner
ATE14226T1 (de)	1985-07-15	Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
DK0506748T3 (da)	1996-01-22	Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
DE69315730D1 (de)	1998-01-29	Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
ATE86260T1 (de)	1993-03-15	Peptid-molekuele, wirksam gegen gram-positive keime.
JPS643161A (en)	1989-01-06	(2-cyano-2-oxyiminoacetyl)-amino acid derivative
DE59108261D1 (de)	1996-11-14	Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69613086D1 (de)	2001-07-05	Antigenen Peptide mit Glycinsubstitution
AU1464488A (en)	1988-10-20	Human rhinovirus peptides
EP1870419A3 (de)	2008-01-02	Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren